Description
BLOOD AND BLOOD PRODUCTS ''IGF::OT::IGF''
First action · last action
2014-10-01 · 2015-12-10
Transactions
4
First transaction's obligation
$320,000
Base + all options value (sum of deltas)
$2,003,494
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
VA24912D0109A
NAICS
621991 · BLOOD AND ORGAN BANKS
Modification chain · 4 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2014-10-01+$320,000= $320,000
- Mod P000012015-06-09-$70,000= $250,000
- Mod P000022015-08-17-$36,000= $214,000
- Mod P000032015-12-10-$18,896= $195,104
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2014-10-01 | +$320,000 | $320,000 | BLOOD AND BLOOD PRODUCTS ''IGF::OT::IGF'' |
| Mod P00001· CHANGE ORDER | 2015-06-09 | −$70,000 | $250,000 | BLOOD AND BLOOD PRODUCTS ''IGF::OT::IGF'' |
| Mod P00002· CHANGE ORDER | 2015-08-17 | −$36,000 | $214,000 | BLOOD AND BLOOD PRODUCTS ''IGF::OT::IGF'' |
| Mod P00003· CHANGE ORDER | 2015-12-10 | −$18,896 | $195,104 | BLOOD AND BLOOD PRODUCTS ''IGF::OT::IGF'' |
Related awards · 9
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI NEVML7ZDHZC7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24926N0117 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $299,043 | FY2026 |
| 36C24925N0051 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $220,676 | FY2025 |
| 36C24924N0066 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $171,294 | FY2024 |
| 36C24923N0116 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $214,347 | FY2023 |
| 36C24923A0004 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36C24922N0027 | 249-NETWORK CONTRACT OFFICE 9 (36C249) · Q508 · MEDICAL- HEMATOLOGY | $156,844 | FY2022 |
Other recipients under Q508 from 596-LEXINGTON (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA24913J0213 | ROCHE DIAGNOSTICS CORPORATION | 596-LEXINGTON | $12,067 | FY2013 |
| VA24913F0105 | CARDINAL HEALTH 200, LLC | 596-LEXINGTON | $282,583 | FY2013 |
| VA596C10005 | TOSOH BIOSCIENCE, INC. | 596-LEXINGTON | $27,000 | FY2011 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24915J24564_3600_VA24912D0109A_3600 · retrieved 2026-09-26.